CPRX
Catalyst Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.49
+0.00%Year over year
Reported trailing growth
- Revenue
- +11.7%
- EBITDA
- +25.1%
- EBIT
- +15.7%
- EPS
- +8.4%
- Free cash flow
- -22.2%
- Operating cash flow
- -22.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +40.1%
- EBITDA
- +44.8%
- EBIT
- +36.3%
- Net income
- +37.1%
- EPS
- +29.8%
- Free cash flow
- +21.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026